

## 2017 Annual Report

### MISSION

*The Leukemia Research Foundation is dedicated to conquering all blood cancers by funding research into their causes and cures, and enriching the quality of life of those touched by these diseases.*

Thank you for your tremendous support during another remarkable year for the Leukemia Research Foundation (LRF). The LRF is stronger than ever due to our continually expanding community that comes together to donate time and resources in support of our important mission.

Thanks to you, the LRF accomplished a number of key objectives during the year. Some of the highlights include:

- For the second time in three years the LRF earned the coveted **4-star rating** from Charity Navigator, the largest charity evaluator in America. The 4-star rating is Charity Navigator's preeminent award for sound fiscal management practices and commitment to accountability and transparency. The rating defines the LRF as "exceptional ... exceeding industry standards and outperforming most charities in its cause."
- The LRF funded ten **blood cancer research projects**, each one year and \$100,000. To distinguish itself in the research community and provide support that is difficult to secure, the LRF exclusively funds New Investigator Research Grants on a worldwide basis. These grants allow innovative scientists to act on their ideas and try new procedures and experiments that will lead to significant breakthroughs.
- The LRF continued to provide need-based, **financial assistance** that reimburses patients for out-of-pocket expenses associated with their blood cancer treatment including co-pays and prescriptions. With more than 500 patients enrolled, tens of thousands in

support was distributed.

- Hundreds were served at the LRF's **educational and support programs** for patients, family members, caregivers and medical professionals. These conferences, including the *Treatment Options for Blood Cancer Patients Conference*, the *Town Hall Meetings*, and the *Family Resource Fair Kids' Party* are offered free of charge or registration. They provide opportunities for direct dialogue between patients and prominent hematology/oncology experts. For the first time, all power point presentations, video, and audio from the *Treatment Options Conference* were posted on the LRF website enabling the information to be fully shared worldwide. Visit [www.allbloodcancers.org/treatment-options-conference](http://www.allbloodcancers.org/treatment-options-conference). It's impressive!

- over please -



### 2017 New Investigator Research Grants

**Sheng Li, Ph.D.**

*Jackson Laboratory, Bar Harbor, ME*  
The role of Sirt2 in the pathogenesis of acute myeloid leukemia

**Britta Will, Ph.D.**

*Albert Einstein College of Medicine*  
Leukemia maintenance through chaperone-mediated autophagy

**Katherine Hyde, Ph.D.**

*University of Nebraska Medical Center*  
The Role of CBFβ-MYH11 in the Maintenance of Leukemia Stem Cells

**Austin Brown, Ph.D.**

*Baylor College of Medicine*  
Pharmacometabolomic Biomarkers of Neuropsychological Outcomes following Pediatric Acute Lymphoblastic Leukemia Therapy

**Wei Du, Ph.D.**

*West Virginia University*  
Targeting niche-stem cell interaction for leukemia therapy

**Jing Li, M.D., Ph.D.**

*Shanghai Normal University, Shanghai, China*  
The role of Sirt2 in the pathogenesis of acute myeloid leukemia

**Parvathi Ranganathan, Ph.D.**

*The Ohio State University*  
Inhibition of PRMT5: a double-edged sword strategy to target acute Graft-versus-Host Disease and relapse/residual disease

**Meelad M. Dawlaty, Ph.D.**

*Albert Einstein College of Medicine*  
Epigenetic regulation of hematopoietic malignancies by Tet enzymes

**Francine E. Garrett-Bakelman, M.D., Ph.D.**

*University of Virginia*  
Determination of age-appropriate risk classification in Acute Myeloid Leukemia

**Sarah A. Slavoff, Ph.D.**

*Yale University*  
Discovery and functional evaluation of non-annotated microproteins in leukemia cells

### 2016-2017 LRF Executive Officers

PRESIDENT

**Larry Mix, Vice President**  
F. H. Paschen, S. N. Nielsen, Inc.

VICE PRESIDENT

**Open**

SECRETARY

**Patty Mix**  
*Joey's Angels Chapter Vice President*  
20+ year volunteer

TREASURER

**Gerald Brin, CPA (Retired)**  
Weltman Bernfield LLC

EXECUTIVE DIRECTOR, *ex officio*

**Kevin Radelet**  
Leukemia Research Foundation

- The inaugural *Road to A Cure – The Latest Developments in Blood Cancer Research* program, made possible in part by the David Wortman Memorial Fund, was held in conjunction with Cancer Wellness Center and featured Dr. Nancy Zeleznik-Le of Loyola University Medical Center who presented on the latest development in hematologic malignancies. Nearly 100 attended.
- Four meetings were held in the Chicago area as part of the newly-established *Multiple Myeloma Rounds* geared toward the medical community and offering Continuing Medical Education credits (CME's). Participation ranged from 100-175

per session. The program will continue in the next year with three sessions in Chicago and expand to Seattle, Atlanta, New York, and Florida.

Thank you for your incredible commitment and dedication. You have touched more lives than you will ever know. Please keep engaged and follow our progress. Regularly visit [www.allbloodcancers.org](http://www.allbloodcancers.org), join us on social media including Facebook, Twitter, and LinkedIn, sign up for the monthly newsletter, contact us, volunteer at events, and/or make a donation.

Again, congratulations and **THANK YOU** to everyone!!




#### Revenue and Other Support


	FYE 2017	FYE 2016
Contributions and grants	2,265,402	2,499,855
Other revenue	2,183	157
<b>Total</b>	<b>2,267,585</b>	<b>2,500,012</b>

#### Expense Allocation

Program service	1,559,622	1,839,543
research	1,132,889	1,294,764
patient financial asst.	236,493	352,381
patient education	190,240	192,398
Management	195,927	200,541
Fundraising	225,959	226,388
<b>Total</b>	<b>1,981,508</b>	<b>2,266,472</b>
<b>change in net assets</b>	<b>286,077</b>	<b>233,540</b>
<b>net assets (end of year)</b>	<b>2,555,287</b>	<b>2,243,475</b>



■ Fundraising ■ Management ■ Program service



## Thank You

The Leukemia Research Foundation sincerely thanks all of its donors, sponsors and supporters, and acknowledges the generous contributions of these donors of \$5,000 or more.

AbbVie, Inc.  
 Alan Boyer Family Foundation  
 Aiden Management Services  
 Amgen, Inc.  
 Anonymous  
 ARIAD Pharmaceuticals  
 Astellas Pharma US, Inc.  
 Be The Match  
 Alan Boyer  
 Helen Brach Foundation  
 Marcia and Harvey Brin  
 C-Quarters Marina, Inc.  
 Celgene Corporation

CFG Community Bank  
 Cole-Crone Family Foundation, Inc.  
 The Coleman Foundation, Inc.  
 Abe and Ida Cooper Foundation  
 The Estate of Bernice Elbin  
 The Estate of Christina R. Elliott  
 Genentech, Inc.  
 Gilead Sciences, Inc.  
 Sheryl Gould  
 Healthcare Foundation of Highland Park  
 David Hunt  
 Janssen Scientific Affairs LLC  
 Jazz Pharmaceuticals, Inc.

Juno Therapeutics, Inc.  
 The Estate of Ethel Maybloom  
 Eugene Minchella  
 Nikoh Foundation  
 Niles North High School  
 Novartis Pharmaceuticals Corp.  
 F.H. Paschen  
 Pfizer Inc.  
 Rush University Medical Center  
 Estate of Florence Sabol  
 Tracy Schwimmer  
 Seattle Genetics

Takeda Oncology  
 (Millennium Pharmaceuticals)  
 Teva Oncology  
 Kenneth W. Thomas Memorial Trust  
 TIF Foundation Fund  
 Turner Construction Company Fndtn.  
 The Drive 97.1-WDRV Chicago\*  
 WLS-TV\*

\* Indicates in-kind gift  
 \*\* indicates in-kind and cash